TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02030496

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open reduction and internal fixation
Description: The surgery will be performed by a certified trauma surgeon. After the fracture site is exposed, the fracture will be reduced and provisionally fixed with K-Wires and reduction forceps. An appropriate volar locking plate which best suits the anatomy of the wrist and the fracture type will be selected. Screw placement and fracture reduction will be confirmed intra-operatively by radiographic images. No post-operative fixation will be applied and patients will be instructed to use the affected extremity in daily activities as pain allows. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Closed reduction and plaster
Description: Closed reduction will be performed according to the Robert-Jones method. This involves increasing the deformity first, then applying continuous traction and immobilising wrist and hand in the reduced position. Additional radiographs will be performed to verify the quality of the reduction. After this has been confirmed, the wrist will be immobilised according to Dutch guidelines: a splint for one week followed by a circular cast for another four weeks. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
Study: NCT04532411

Intervention type: OTHER
Intervention: Personal Protective Testing Booth
Description: Health personnel who utilize the Hexapod will remain in the booth and utilize durable gloves attached to ports through a plexiglass wall in order to administer a nasal swab for SARS-CoV-2 (COVID-19) testing. Patient escorts and housekeeping/sanitation staff perform additional tasks outside of the booth such as escorting the patient to the correct testing bay and dropping off testing vials and printed information, collect samples and deposit in the appropriate location after testing is complete, and sanitizing the patient bay before a subsequent patient is tested there.
Study: NCT00636961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300μg
Description: 300μg indacaterol maleate inhalation powder in hard gelatin capsules administered via Concept1 inhalation device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300μg
Description: 300μg indacaterol maleate inhalation powder in hard gelatin capsules administered via Concept1 inhalation device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo devices and hard gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo devices and hard gelatin capsules
Study: NCT05266859

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: Calcium hydroxide in the power/liquid form will be used and placed on the exposed pulp

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTA
Description: Mineral trioxide aggregate will be used as a powder / liquid form and placed over the exposed pulp

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRF
Description: PRF will be placed directly over the exposed pulp
Study: NCT01687842

Intervention type: OTHER
Intervention: Evaluation of 45,X Turner syndrome patients
Description: Evaluation of 45,X Turner syndrome patients
Study: NCT02045732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 0.25 mg/kg
Description: Bi-Weekly Subcutaneous Injections X 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Bi-Weekly Subcutaneous Injections X 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Bi-Weekly Subcutaneous Injections X 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Bi-Weekly Subcutaneous Injections X 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Bi-Weekly Subcutaneous Injections X 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 1.5 mg/kg
Description: Bi-Weekly Subcutaneous Injections X 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 6.0 mg/kg
Description: Bi-Weekly Subcutaneous Injections X 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 6.0 mg/kg
Description: Bi-Weekly Subcutaneous Injections X 6
Study: NCT01870297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3025876
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3025876
Description: Administered SQ

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SQ

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Administered SQ

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide
Description: Administered SQ
Study: NCT00770666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch, nicotine inhaler, bupropion
Description: Patch - 21 mg - taper as able Inhaler - as needed Bupropion SR 150 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: 21 mg daily for 6 weeks followed by 14 mg for 2 weeks and then 7 mg for 2 weeks
Study: NCT02477709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant oral tablet (150 mg administered as three 50 mg tablets) - single dose only
Study: NCT01635309

Intervention type: OTHER
Intervention: Coronary CT Angiogram
Description: pre-operative coronary CTA
Study: NCT01488396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05%cyclosporin eye drop
Description: use twice daily for 6 months
Study: NCT02770846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate loading

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed loading
Study: NCT04212975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: joint lavage with dextrose
Description: joint lavage with dextrose
Study: NCT02471482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mozart music lullaby
Description: Recorded Mozart Lullaby will be played. The noise level will be kept below 45db as recommended by American Academy of Pediatrics and will be monitored by sound monitor placed in incubator during the study period. Enrolled babies will have hearing screening performed prior to discharge from hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mozart music lullaby
Description: Recorded Mozart Lullaby will be played. The noise level will be kept below 45db as recommended by American Academy of Pediatrics and will be monitored by sound monitor placed in incubator during the study period. Enrolled babies will have hearing screening performed prior to discharge from hospital.
Study: NCT05595811

Intervention type: OTHER
Intervention: outcome following surgery

Intervention type: OTHER
Intervention: outcome following surgery
Study: NCT04485754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine FU
Description: Participant will get telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Office FU
Description: Participant will get office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
Study: NCT02089412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006
Study: NCT01301703

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)
Description: a single 0.5-mL intramuscular injection into the deltoid muscle of the upper arm
Study: NCT03121209

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Revascularization
Description: Patients in this arm are randomized to CEA/CAS plus IMM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Medical Management (IMM) alone
Description: Patients in this arm are randomized to intensive medical management (IMM) alone
Study: NCT03634306

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultravision System
Description: Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultravision System
Description: Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Laparoscopic Hysterectomy
Description: Laparoscopic hysterectomy will be performed according to standard of care without the Ultravision Visual Field Clearing System
Study: NCT00776659

Intervention type: OTHER
Intervention: Aromasin
Description: Non-Interventional study design.
Study: NCT00037713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BEC2 Vaccine
Description: 5 vaccinations of BEC2 (2.5 mg) + BCG given day 1 of weeks 0,2,4,6 \& 10.
Study: NCT02414347

Intervention type: DRUG
Intervention: F 18 T807
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study: NCT02869945

Intervention type: GENETIC
Group type: OTHER
Intervention: Identification of COMT HH, COMT HL or COMT LL genes
Description: COMT HH, COMT HL or COMT LL genes identification

Intervention type: GENETIC
Group type: OTHER
Intervention: Identification of COMT HH, COMT HL or COMT LL genes
Description: COMT HH, COMT HL or COMT LL genes identification

Intervention type: GENETIC
Group type: OTHER
Intervention: Identification of COMT HH, COMT HL or COMT LL genes
Description: COMT HH, COMT HL or COMT LL genes identification

Intervention type: OTHER
Group type: OTHER
Intervention: Brain MRI with resting state scan
Description: MRI scan with resting state study to be performed to assess the compensation mechanisms at the networks level.

Intervention type: OTHER
Group type: OTHER
Intervention: Brain MRI with resting state scan
Description: MRI scan with resting state study to be performed to assess the compensation mechanisms at the networks level.

Intervention type: OTHER
Group type: OTHER
Intervention: Brain MRI with resting state scan
Description: MRI scan with resting state study to be performed to assess the compensation mechanisms at the networks level.

Intervention type: OTHER
Group type: OTHER
Intervention: Brain MPET
Description: Monophotonic emission tomography with I-123-Ioflupane to assess the level of dopaminergic denervation.

Intervention type: OTHER
Group type: OTHER
Intervention: Brain MPET
Description: Monophotonic emission tomography with I-123-Ioflupane to assess the level of dopaminergic denervation.

Intervention type: OTHER
Group type: OTHER
Intervention: Brain MPET
Description: Monophotonic emission tomography with I-123-Ioflupane to assess the level of dopaminergic denervation.
Study: NCT02560389

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill packaged to resemble levodopa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Description: EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Description: EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.
Study: NCT02049112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Salivary equivalent
Description: 14-day treatment with salivary equivalent sticks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Aequasyal
Description: 14-day treatment with Aequasyal oral spray

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Biotene
Description: 14-day treatment with Biotene oral spray
Study: NCT02716298

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fanfilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: contact lens
Study: NCT02314104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
Study: NCT00941642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza
Description: Approximately 50% of study subjects will be randomized to the active treatment arm -Lovaza. Subjects will be dosed with 4g of Lovaza gel capsules daily for a minimum of 48 weeks duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: Approximately 50% of study subjects will be randomized to the placebo arm of this study. Placebo arm subjects will receive 4g of placebo gel caps daily for a minimum of 48 weeks duration.
Study: NCT00269477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study: NCT03442699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.
Study: NCT03145051

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline solution
Description: a nasal irrigation care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respimer Netiflow
Description: a nasal irrigation care
Study: NCT00523523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy + auditory rhythm cues
Description: The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. Participants in the experimental group will perform this practice to the beat of a metronome. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constraint-Induced Movement Therapy
Description: The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
Study: NCT03209518

Intervention type: DRUG
Intervention: Leuprorelin acetate
Description: Leuplin PRO for Injection Kit 22.5 mg
Study: NCT03163459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selective brain cooling by cold saline perfusion
Description: During the procedure, a microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical thrombectomy
Description: conventional mechanical thrombectomy using Solitaire
Study: NCT01192776

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole-body Cooling
Description: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole-body Cooling
Description: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole-body Cooling
Description: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Whole-body Cooling
Description: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.
Study: NCT03163459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical thrombectomy
Description: conventional mechanical thrombectomy using Solitaire
Study: NCT03257969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The DROP program of pharmaceutical interventions
Description: Multidisciplinary program that includes informative sessions with a hospital pharmacist about the oral anticancer drug: information is given to the patient on adverse events occurrence and there management; and optimizing drug dosage plan, including drug-drug interactions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of care
Description: In the group with standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessment.
Study: NCT00966355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin
Description: loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days
Study: NCT01028495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-0201 plus Gemcitabine
Description: RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off. Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.
Study: NCT03706001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychotherapy has gained increasing acceptance as a major treatment option for mood disorders.
Study: NCT02175342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 0.625 mcg/puff

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 1.25 mcg/puff

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 mcg/puff

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 mcg/puff

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium-18 lactose powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lactose powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 10 mcg/puff

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Respimat

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Handihaler

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Handihaler